Functional studies of embryonic
epsilon-globin indicate that individuals with
beta thalassemia or
sickle cell disease are likely to benefit from therapeutic, transcriptional derepression of its encoding gene. The success of
epsilon-globin gene-reactivation strategies, however, will be tempered by the stability that
epsilon-globin mRNA exhibits in developmental stage-discordant definitive erythroid progenitors. Using cell culture and transgenic mouse model systems, we demonstrate that
epsilon-globin mRNA is modestly unstable in immature, transcriptionally active erythroid cells, but that this characteristic has relatively little impact on the accumulation of
epsilon-globin mRNA at subsequent stages of terminal differentiation. Importantly, the constitutive stability of
epsilon-globin mRNA increases in transgenic mouse models of
beta thalassemia, suggesting that epsilon- and
beta-globin mRNAs are coregulated through a shared posttranscriptional mechanism. As anticipated, relevant cis-acting determinants of
epsilon-globin mRNA stability map to its
3' UTR, consistent with the positioning of functionally related elements in other
globin mRNAs. These studies demonstrate that posttranscriptional processes do not pose a significant practical barrier to
epsilon-globin gene reactivation and, moreover, indicate that related therapeutic strategies may be particularly effective in individuals carrying beta-thalassemic gene defects.